breast cancer

AstraZeneca's Lynparza Slows Breast Cancer Caused By BRCA Mutations By 42%
Forbes
Sun, 06/4/17 - 11:53 am
AstraZeneca
Lynparza
breast cancer
BRCA-mutant breast cancer
ASCO 2017
FDA Panel Votes 12 To 4 to Approve Puma's Breast Cancer Drug
Forbes
Thu, 05/25/17 - 08:51 am
FDA
Puma Biotechnology
breast cancer
advisory panels
neratinib
Puma Biotechnology FDA Live Blog
Forbes
Wed, 05/24/17 - 10:39 am
FDA
Puma Biotechnology
advisory panels
neratinib
breast cancer
Pfizer bows first Ibrance TV spot as Novartis revs up with rival breast cancer med Kisqali
Fierce Pharma
Wed, 05/24/17 - 10:37 am
Pfizer
Ibrance
Novartis
breast cancer
drug ads
Puma shares jump 40% after FDA review but brief leaves scope for AdComm grilling and neratinib rejection
Fierce Biotech
Tue, 05/23/17 - 08:13 am
Puma Biotechnology
neratinib
breast cancer
FDA review raises some serious questions for Puma, but shares rocket up on positive notes
Endpoints
Mon, 05/22/17 - 10:21 am
FDA
Puma Biotechnology
neratinib
breast cancer
advisory panels
Astellas, Pfizer scrap a PhIII breast cancer study using Xtandi; New $30M fund will back Israeli biotech startups
Endpoints
Sat, 05/20/17 - 12:50 pm
Astellas
Pfizer
breast cancer
clinical trials
Xtandi
Israel
biotech
ASCO: Lilly's abemaciclib vs. Pfizer's Ibrance? Too early to make a call, analysts say
Fierce Pharma
Thu, 05/18/17 - 08:00 pm
ASCO 2017
Eli Lilly
Pfizer
abemaciclib
Ibrance
breast cancer
Pfizer, awaiting a final NICE verdict, doles out free Ibrance in the U.K.
Fierce Pharma
Sun, 05/7/17 - 10:23 am
Pfizer
Ibrance
NICE
UK
breast cancer
Roche silently whisks away its $1.7B Seragon drug in a Q1 footnote
Endpoints
Thu, 04/27/17 - 09:25 am
Roche
Seragon
earnings
breast cancer
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug
TheStreet.com
Tue, 04/18/17 - 09:13 pm
FDA
advisory panels
Puma Biotechnology
neratinib
breast cancer
Rivals multiplying, Pfizer appeals to doctor preferences with Ibrance's latest label win
Fierce Pharma
Tue, 04/4/17 - 10:58 pm
Pfizer
Ibrance
Novartis
Kisqali
Eli Lilly
abemaciclib
HER-2 negative breast cancer
breast cancer
Pfizer's Ibrance Gets FDA Approval for Breast Cancer
Investopedia
Mon, 04/3/17 - 11:54 am
Pfizer
Ibrance
breast cancer
FDA
Investigational Breast Cancer Drug Could Boost Novartis’s Position
Marketwatch
Mon, 04/3/17 - 11:52 am
breast cancer
Novartis
LEE011
Phase 3 win moves Lilly's breast cancer drug closer to market
BioPharma Dive
Mon, 03/20/17 - 11:31 pm
Eli Lilly
breast cancer
abemaciclib
Lilly's breast cancer drug combination succeeds key study
Yahoo/Reuters
Mon, 03/20/17 - 10:49 am
Eli Lilly
clinical trials
breast cancer
abemaciclib
Will Pfizer's Growth Be Threatened by Novartis' New Cancer Drug?
Motley Fool
Wed, 03/15/17 - 09:52 pm
Novartis
Pfizer
breast cancer
Ibrance
Kisqali
Watch out Pfizer, Novartis’ LEE011 bags quick OK for frontline use against breast cancer
Endpoints
Tue, 03/14/17 - 09:38 am
Pfizer
Novartis
LEE011
Ibrance
ribociclib
Kisqali
breast cancer
Roche and Mylan settle a scrap over Herceptin, clearing path to a global launch of a knockoff drug
Endpoints
Mon, 03/13/17 - 10:13 am
Roche
Mylan Labs
Herceptin
Perjeta
breast cancer
Top Biotech Stocks With FDA Decisions in 2017
Motley Fool
Fri, 03/3/17 - 09:42 am
FDA
Flexion
Zilretta
knee pain
osteoarthritis
neratinib
Puma Biotechnology
breast cancer
Portola
betrixaban
bloodthinners

Pages